ArticleCancer biology & therapy2013
Daunomycin, an antitumor DNA intercalator, influences histone-DNA interactions.
Article in Cancer biology & therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 31 citations in OpenAlex.
- Aclarubicin stimulates RNA polymerase II elongation at closely spaced divergent promoters.Science advances · 2023Article
- The Anticancer Drug Daunomycin Directly Affects Gene Expression and DNA Structure.International journal of molecular sciences · 2023Article
- Aclarubicin stimulates RNA polymerase II elongation at closely spaced divergent promoters.bioRxiv : the preprint server for biology · 2023Article
- Doxorubicin impacts chromatin binding of HMGB1, Histone H1 and retinoic acid receptor.Scientific reports · 2022Article
- Translocation of chromatin proteins to nucleoli-The influence of protein dynamics on post-fixation localization.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2021Article
- Biophysical Characterization and Anticancer Activities of Photosensitive Phytoanthraquinones Represented by Hypericin and Its Model Compounds.Molecules (Basel, Switzerland) · 2020Review
- Topoisomerases inhibition and DNA binding mode of daunomycin-oligoarginine conjugate.Journal of enzyme inhibition and medicinal chemistry · 2020Article
- Doxorubicin induces large-scale and differential H2A and H2B redistribution in live cells.PloS one · 2020Article
- Molecular Recognition of Parallel G-quadruplex [d-(TTGGGGT)]₄ ContainingMolecules (Basel, Switzerland) · 2018Article
- Role of Chromatin Damage and Chromatin Trapping of FACT in Mediating the Anticancer Cytotoxicity of DNA-Binding Small-Molecule Drugs.Cancer research · 2018Article
- Nucleosome stability measured in situ by automated quantitative imaging.Scientific reports · 2017Article
- Spatial heterogeneity of dynamics of H1 linker histone.European biophysics journal : EBJ · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although daunomycin and adriamycin are considered effective antitumor drugs and have been used in the clinic for over 40 years, their mechanism of action is still a matter of debate. We investigated the influence of daunomycin on interaction between linker or core histones and DNA in live HeLa cells in vitro, using image and flow cytometry. Exposure to daunomycin at clinically relevant concentrations (25-250 nM) caused dissociation of wild-type H1.1 as well as 4 H1 point mutants from DNA, followed by their accumulation in nucleoli and aggregation of chromatin. A detectable dissociation of H2B core histones occurred only at much higher concentrations of the drug (500 nM). Replication of DNA and synthesis of RNA were not halted by daunomycin (up to 2500 nM); however the characteristic subnuclear distribution of sites of transcription and replication was lost. Dissociation of the H1.1 linker histones and subsequent loss of higher order chromatin structures may constitute an important component of the mechanism of cytotoxicity of daunomycin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.